Drug Trial Radar · NCT07169318
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Sep 16, 2025
Primary completion
May 1, 2027
Study completion May 1, 2027
Sponsor
- Sponsor type
- NIH
- First posted
- Sep 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 59 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo-controlled Phase 1 study conducted at a single center with approximately 78 healthy adults aged 18-59 years. Part 1 Single Ascending Dose (SAD) will enroll 48 participants into six cohorts (S1-S6) to receive single oral doses of VNT-101 (100-1500 mg) or placebo under fasting or fed (S5 only) conditions. Part 2 Multiple Ascending Dose (MAD) will enroll 30 participants into three cohorts (M1-M3) to receive multiple oral doses of VNT-101 (250-750 mg BID Days 1-5, QD Day 6) or placebo under fasting conditions. Dose escalation in both parts will proceed after Protocol Safety Review Team (PSRT) review. The primary objective for Part 1 is to evaluate the safety and tolerability of single ascending oral (SAD) doses of VNT-101 in healthy adult participants under either fasting or fed conditions. The primary objective for part 2 is to evaluate the safety and tolerability of multiple ascending oral (MAD) doses of VNT-101 in healthy adult participants.
Conditions
- Influenza
Interventions
Placebo for VNT-101Other
Capsules will be size 00 and filled with microcrystalline cellulose
VNT-101Drug
VNT-101 is an orally bioavailable, direct-acting antiviral with a novel mechanism of action - inhibiting oligomerization of the influenza nucleoprotein (NP) and thereby inhibiting viral ribonucleic acid (RNA) synthesis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Grade change from baseline in any 12-lead ECG readingTime frame: Day 1 through Day 13
- Grade change from baseline in any clinical laboratory parameterTime frame: Day 1 through Day 13
- Grade change from baseline in any vital signTime frame: Day 1 through Day 13
- Incidence of Treatment Emergent Adverse Events (TEAEs)Time frame: Day 1 through Day 13
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Altasciences Inc - Kansas City
Overland Park, Kansas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.